IRIS
GOBBI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 28.395
AS - Asia 27
SA - Sud America 6
NA - Nord America 1
Totale 28.429
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.395
CN - Cina 19
VN - Vietnam 5
BR - Brasile 4
SG - Singapore 3
AR - Argentina 1
CL - Cile 1
US - Stati Uniti d'America 1
Totale 28.429
Salva come PNG Salva come JPEG
Città #
Genova 18.691
Genoa 5.872
Rapallo 2.346
Vado Ligure 1.426
Bordighera 56
Beijing 6
Hanoi 3
Perugia 3
Singapore 2
Ashburn 1
Camboriú 1
Campos dos Goytacazes 1
Manaus 1
Phủ Lý 1
Quảng Ngãi 1
Santa Sylvina 1
Santiago 1
Tocantinópolis 1
Totale 28.414
Salva come PNG Salva come JPEG
Nome #
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. 364
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 218
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 208
APO866 activity in hematologic malignancies: a preclinical in vitro study. 203
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 191
Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts 183
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 180
M-2 protocol for melphalan-resistant and relapsing multiple myeloma. 179
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 179
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 176
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 175
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 174
A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies 173
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study 170
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 167
Randomized trial of Fludarabine versus fludarabine and Idarubicin as Frontline treatment in patients with indolent or mantle-cell lymphoma 166
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 165
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 165
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma 164
Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF 163
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 162
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. 158
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 158
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 157
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 157
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 155
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. 153
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 153
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 152
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 151
Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia 151
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 151
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 149
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 149
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 147
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 147
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. 146
Thalidomide in agnogenic and secondary myelofibrosis 146
HIV-related malignant lymphoma: a report of 46 cases observed in Italy. 145
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. 145
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies 145
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 145
Anaplastic large cell lymphoma: a clinicopathologic study of 53 patients. 144
An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells. 144
Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor V? 2 T lymphocytes in non-Hodgkin lymphomas 144
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 144
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 143
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 143
T lymphocyte subsets and colony growth in hairy-cell leukemia. 142
Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report 140
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease 138
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. 138
Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis 137
[Allogeneic bone marrow transplantation in multiple myeloma]. 137
Targeting of a plasma cell line with a conjugate containing xanthine oxidase and the monoclonal antibody 62B1. 137
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 137
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 137
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 136
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 136
Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia. 136
An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients. 135
Evidence for killing of Mesenchymal Stem Cells (MSC) by autologous natural killer lymphocytes. 135
Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells 134
IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia 134
Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. 134
Hodgkin's disease (HD): a historical perspective. 133
New insights into biology of chronic myeloid leukemia: implications in therapy. 133
Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. 132
Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura 131
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 131
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 131
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 130
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 130
A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies. 129
Vimentin and keratin intermediate filaments expression by K562 leukemic cell line. 129
Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. 129
Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies. 129
CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: preliminary report. 128
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 128
The addition of radiotherapy to chemotherapy does not improve outcome of early stage Hodgkin's lymphoma patients: a retrospective long-term follow-up analysis of a regional Italian experience. 128
An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) grows in SCID-mice with the features of a CD30+ anaplastic large cell lymphoma and is sensitive to anti-CD30 immunotoxins 127
Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. 126
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 126
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 126
Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization. 126
An immunotoxin made up with campath 1 and saporin 6: preliminary "in vitro" experience. 126
Prognostic variables and clinical staging in multiple myeloma. 125
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia 125
Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma 124
Laparoscopic splenectomy for hematological diseases. 124
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. 124
The value of lymph node biopsy in patients with the acquired immunodeficiency syndrome (AIDS) and the AIDS-related complex (ARC): a morphological and immunohistochemical study of 90 cases. 123
Bone marrow transplantation in multiple myeloma. 123
Multimarker phenotypic characterization of adult and childhood acute lymphoblastic leukaemia: an Italian multicentre study. 123
High-dose melphalan for multiple myeloma. 123
Lonidamine in the treatment of chronic lymphoid leukemia. 123
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 122
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 122
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 122
CTLA-4 +49A>G polymorphism of recipients of HLA-matched sibling allogeneic stem cell transplantation is associated with survival and relapse incidence. 122
Totale 14.703
Salva come PNG Salva come JPEG
Categoria #
all - tutte 83.652
article - articoli 82.669
book - libri 0
conference - conferenze 242
curatela - curatele 0
other - altro 320
patent - brevetti 0
selected - selezionate 0
volume - volumi 421
Totale 167.304
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.164 0 0 0 103 100 147 63 137 149 175 136 154
2021/20222.848 78 210 206 293 174 180 158 679 93 295 98 384
2022/20232.839 306 163 38 272 506 554 11 235 470 35 211 38
2023/20241.387 68 189 33 143 128 295 61 128 64 21 76 181
2024/20253.710 67 327 114 227 450 347 346 596 105 155 460 516
2025/20261.807 851 163 323 470 0 0 0 0 0 0 0 0
Totale 28.642